Brief: Rocket Pharma Receives European Medicines Agency Priority Medicines Designation For Gene Therapy For Danon Disease
31/05/2023 12:33
May 31 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O :
* ROCKET PHARMACEUTICALS RECEIVES EUROPEAN MEDICINES AGENCY
(EMA)
PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-A501 GENE THERAPY
FOR DANON DISEASE
Source text for Eikon: ID:nBw4n8NjPa
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08